Hypoxia-inducible factor prolyl hydroxylases as targets for neuroprotection by "antioxidant" metal chelators: From ferroptosis to stroke

Free Radical Biology and Medicine

Volumn 62, Issue , 2013, Pages 26-36

  Speer, Rachel E ^a,b   Karuppagounder, Saravanan S ^a,b   Basso, Manuela ^a,b   Sleiman, Sama F ^a,b   Kumar, Amit ^a,b   Brand, David ^a,b   Smirnova, Natalya ^a,b   Gazaryan, Irina ^a,b   Khim, Soah J ^a,b   Ratan, Rajiv R ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b BURKE MEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

Free radicals; Hypoxia inducible factors; Metal chelators; Neurodegeneration; Prolyl hydroxylases; Transcription

Indexed keywords

ANTIOXIDANT; CHELATING AGENT; DEFEROXAMINE; DIMETHYLOXALYLGLYCINE; ETHYL 3,4 DIHYDROXY BENZOIC ACID; FIBRINOLYTIC AGENT; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; METAL; OXYGEN; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROTEIN P53; TISSUE PLASMINOGEN ACTIVATOR; UBIQUITIN; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

ADAPTATION; ALZHEIMER DISEASE; APOPTOSIS; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; ENZYME DEGRADATION; FERROPTOSIS; FRIEDREICH ATAXIA; HUMAN; HUNTINGTON CHOREA; HYDROXYLATION; MOLECULAR MECHANICS; NERVE DEGENERATION; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STABILITY; PROTEIN SYNTHESIS; PROTEIN TARGETING; REVIEW; TRANSCRIPTION REGULATION; TRANSLATION REGULATION; UNITED STATES;

ANIMALIA;

EID: 84884900556     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2013.01.026     Document Type: Review

References (140)

1. Dixon, S. J.; Lemberg, K. M.; Lamprecht, M. R.; Skouta, R.; Zaitsev, E. M.; Gleason, C. E.; Patel, D. N.; Bauer, A. J.; Cantley, A. M.; Yang, W. S.; Morrison 3rd B.; Stockwell, B. R. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149: 1060-1072; 2012.
2. Ryu, H.; Lee, J.; Zaman, K.; Kubilis, J.; Ferrante, R. J.; Ross, B. D.; Neve, R.; Ratan, R. R. Sp1 and Sp3 are oxidative stress-inducible, antideath transcription factors in cortical neurons. J. Neurosci. 23: 3597-3606; 2003. (Pubitemid 36958467)
3. Lange, P. S.; Chavez, J. C.; Pinto, J. T.; Coppola, G.; Sun, C. W.; Townes, T. M.; Geschwind, D. H.; Ratan, R. R. ATF4 is an oxidative stress-inducible, prodeath transcription factor in neurons in vitro and in vivo. J. Exp. Med. 205: 1227-1242; 2008. (Pubitemid 351679695)
4. Ryu, H.; Lee, J.; Olofsson, B. A.; Mwidau, A.; Dedeoglu, A.; Escudero, M.; Flemington, E.; Azizkhan-Clifford, J.; Ferrante, R. J.; Ratan, R. R. Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway. Proc. Natl. Acad. Sci. USA 100: 4281-4286; 2003. (Pubitemid 36418194)
5. Siddiq, A.; Ayoub, I. A.; Chavez, J. C.; Aminova, L.; Shah, S.; LaManna, J. C.; Patton, S. M.; Connor, J. R.; Cherny, R. A.; Volitakis, I.; Bush, A. I.; Langsetmo, I.; Seeley, T.; Gunzler, V.; Ratan, R. R. Hypoxia-inducible factor prolyl 4-hydroxylase inhibition: a target for neuroprotection in the central nervous system. J. Biol. Chem. 280: 41732-41743; 2005. (Pubitemid 41832236)
6. McConoughey, S. J.; Basso, M.; Niatsetskaya, Z. V.; Sleiman, S. F.; Smirnova, N. A.; Langley, B. C.; Mahishi, L.; Cooper, A. J.; Antonyak, M. A.; Cerione, R. A.; Li, B.; Starkov, A.; Chaturvedi, R. K.; Beal, M. F.; Coppola, G.; Geschwind, D. H.; Ryu, H.; Xia, L.; Iismaa, S. E.; Pallos, J.; Pasternack, R.; Hils, M.; Fan, J.; Raymond, L. A.; Marsh, J. L.; Thompson, L. M.; Ratan, R. R. Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease. EMBO Mol. Med 2: 349-370; 2010.
7. Sleiman, S. F.; Langley, B. C.; Basso, M.; Berlin, J.; Xia, L.; Payappilly, J. B.; Kharel, M. K.; Guo, H.; Marsh, J. L.; Thompson, L. M.; Mahishi, L.; Ahuja, P.; MacLellan, W. R.; Geschwind, D. H.; Coppola, G.; Rohr, J.; Ratan, R. R. Mithramycin is a gene-selective Sp1 inhibitor that identifies a biological intersection between cancer and neurodegeneration. J. Neurosci. 31: 6858-6870; 2011.
8. Cooper, G. M. The Cell: a Molecular Approach. Sunderland (MA): Sinauer; 2000.
9. Gorres, K. L.; Raines, R. T. Prolyl 4-hydroxylase. Crit. Rev. Biochem. Mol. Biol. 45: 106-124; 2010.
10. Loenarz, C.; Coleman, M. L.; Boleininger, A.; Schierwater, B.; Holland, P. W.; Ratcliffe, P. J.; Schofield, C. J. The hypoxia-inducible transcription factor pathway regulates oxygen sensing in the simplest animal, Trichoplax adhaerens. EMBO Rep. 12: 63-70; 2011.
11. Wang, G. L.; Semenza, G. L. Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. J. Biol. Chem. 268: 21513-21518; 1993. (Pubitemid 23320639)
12. Uniacke, J.; Holterman, C. E.; Lachance, G.; Franovic, A.; Jacob, M. D.; Fabian, M. R.; Payette, J.; Holcik, M.; Pause, A.; Lee, S. An oxygen-regulated switch in the protein synthesis machinery. Nature 486: 126-129; 2012.
13. Wang, V.; Davis, D. A.; Haque, M.; Huang, L. E.; Yarchoan, R. Differential gene up-regulation by hypoxia-inducible factor-1alpha and hypoxia-inducible factor-2alpha in HEK293T cells. Cancer Res. 65: 3299-3306; 2005. (Pubitemid 40524614)
14. Bruick, R. K.; McKnight, S. L. A conserved family of prolyl-4- hydroxylases that modify HIF. Science 294: 1337-1340; 2001. (Pubitemid 33063099)
15. Ivan, M.; Kondo, K.; Yang, H.; Kim, W.; Valiando, J.; Ohh, M.; Salic, A.; Asara, J. M.; Lane, W. S.; Kaelin Jr. W. G. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292: 464-468; 2001. (Pubitemid 32335941)
16. Jaakkola, P.; Mole, D. R.; Tian, Y. M.; Wilson, M. I.; Gielbert, J.; Gaskell, S. J.; von Kriegsheim, A.; Hebestreit, H. F.; Mukherji, M.; Schofield, C. J.; Maxwell, P. H.; Pugh, C. W.; Ratcliffe, P. J. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292: 468-472; 2001. (Pubitemid 32335942)
17. Jiang, B. H.; Rue, E.; Wang, G. L.; Roe, R.; Semenza, G. L. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J. Biol. Chem. 271: 17771-17778; 1996. (Pubitemid 26250751)
18. Jeong, J. W.; Bae, M. K.; Ahn, M. Y.; Kim, S. H.; Sohn, T. K.; Bae, M. H.; Yoo, M. A.; Song, E. J.; Lee, K. J.; Kim, K. W. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 111: 709-720; 2002. (Pubitemid 35441252)
19. Kamura, T.; Koepp, D. M.; Conrad, M. N.; Skowyra, D.; Moreland, R. J.; Iliopoulos, O.; Lane, W. S.; Kaelin Jr. W. G.; Elledge, S. J.; Conaway, R. C.; Harper, J. W.; Conaway, J. W. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 284: 657-661; 1999. (Pubitemid 29289593)
20. Fraisl, P.; Aragones, J.; Carmeliet, P. Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease. Nat. Rev. Drug Discovery 8: 139-152; 2009.
21. Chan, D. A.; Sutphin, P. D.; Yen, S. E.; Giaccia, A. J. Coordinate regulation of the oxygen-dependent degradation domains of hypoxia-inducible factor 1 alpha. Mol. Cell. Biol. 25: 6415-6426; 2005. (Pubitemid 41023218)
22. Appelhoff, R. J.; Tian, Y. M.; Raval, R. R.; Turley, H.; Harris, A. L.; Pugh, C. W.; Ratcliffe, P. J.; Gleadle, J. M. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J. Biol. Chem. 279: 38458-38465; 2004. (Pubitemid 39295997)
23. Marxsen, J. H.; Stengel, P.; Doege, K.; Heikkinen, P.; Jokilehto, T.; Wagner, T.; Jelkmann, W.; Jaakkola, P.; Metzen, E. Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-alpha-prolyl-4- hydroxylases. Biochem. J. 381: 761-767; 2004. (Pubitemid 39120486)
24. Landazuri, M. O.; Vara-Vega, A.; Viton, M.; Cuevas, Y.; del Peso, L. Analysis of HIF-prolyl hydroxylases binding to substrates. Biochem. Biophys. Res. Com-mun. 351: 313-320; 2006. (Pubitemid 44666691)
25. Xie, L.; Xiao, K.; Whalen, E. J.; Forrester, M. T.; Freeman, R. S.; Fong, G.; Gygi, S. P.; Lefkowitz, R. J.; Stamler, J. S. Oxygen-regulated beta(2)-adrenergic receptor hydroxylation by EGLN3 and ubiquitylation by pVHL. Sci. Signaling 2:ra33; 2009.
26. Mikhaylova, O.; Ignacak, M. L.; Barankiewicz, T. J.; Harbaugh, S. V.; Yi, Y.; Maxwell, P. H.; Schneider, M.; Van Geyte, K.; Carmeliet, P.; Revelo, M. P.; Wyder, M.; Greis, K. D.; Meller, J.; Czyzyk-Krzeska, M. F. The von Hippel-Lindau tumor suppressor protein and Egl-9-type proline hydroxylases regulate the large subunit of RNA polymerase II in response to oxidative stress. Mol. Cell. Biol. 28: 2701-2717; 2008. (Pubitemid 351542369)
27. Zhang, Q.; Gu, J.; Li, L.; Liu, J.; Luo, B.; Cheung, H. W.; Boehm, J. S.; Ni, M.; Geisen, C.; Root, D. E.; Polyak, K.; Brown, M.; Richardson, A. L.; Hahn, W. C.; Kaelin Jr. W. G.; Bommi-Reddy, A. Control of cyclin D1 and breast tumor-igenesis by the EglN2 prolyl hydroxylase. Cancer Cell 16: 413-424; 2009.
28. Boulahbel, H.; Duran, R. V.; Gottlieb, E. Prolyl hydroxylases as regulators of cell metabolism. Biochem. Soc. Trans. 37: 291-294; 2009.
29. Aragones, J.; Fraisl, P.; Baes, M.; Carmeliet, P. Oxygen sensors at the crossroad of metabolism. Cell Metab. 9: 11-22; 2009.
30. Hirsila, M.; Koivunen, P.; Gunzler, V.; Kivirikko, K. I.; Myllyharju, J. Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J. Biol. Chem. 278: 30772-30780; 2003. (Pubitemid 36994584)
31. Chua, Y. L.; Dufour, E.; Dassa, E. P.; Rustin, P.; Jacobs, H. T.; Taylor, C. T.; Hagen, T. Stabilization of hypoxia-inducible factor-1alpha protein in hypoxia occurs independently of mitochondrial reactive oxygen species production. J. Biol. Chem. 285: 31277-31284; 2010.
32. Hagen, T.; Taylor, C. T.; Lam, F.; Moncada, S. Redistribution of intracellular oxygen in hypoxia by nitric oxide: effect on HIF1alpha. Science 302: 1975-1978; 2003. (Pubitemid 37523507)
33. Emerling, B. M.; Platanias, L. C.; Black, E.; Nebreda, A. R.; Davis, R. J.; Chandel, N. S. Mitochondrial reactive oxygen species activation of p38 mitogen-activated protein kinase is required for hypoxia signaling. Mol. Cell. Biol. 25: 4853-4862; 2005. (Pubitemid 40781087)
34. Sandau, K. B.; Zhou, J.; Kietzmann, T.; Brune, B. Regulation of the hypoxia-inducible factor 1alpha by the inflammatory mediators nitric oxide and tumor necrosis factor-alpha in contrast to desferroxamine and phenylarsine oxide. J. Biol. Chem 276: 39805-39811; 2001.
35. Maxwell, P. H.; Wiesener, M. S.; Chang, G. W.; Clifford, S. C.; Vaux, E. C.; Cockman, M. E.; Wykoff, C. C.; Pugh, C. W.; Maher, E. R.; Ratcliffe, P. J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275; 1999. (Pubitemid 29246458)
36. Nyhan, M. J.; O'Sullivan, G. C.; McKenna, S. L. Role of the VHL (von Hippel-Lindau) gene in renal cancer: a multifunctional tumour suppressor. Bio-chem. Soc. Trans. 36: 472-478; 2008. (Pubitemid 351839358)
37. Zhou, M. I.; Wang, H.; Ross, J. J.; Kuzmin, I.; Xu, C.; Cohen, H. T. The von Hippel-Lindau tumor suppressor stabilizes novel plant homeodomain protein Jade-1. J. Biol. Chem. 277: 39887-39898; 2002. (Pubitemid 35190975)
38. Etlinger, J. D.; Goldberg, A. L. A soluble ATP-dependent proteolytic system responsible for the degradation of abnormal proteins in reticulocytes. Proc. Natl. Acad. Sci. USA 74: 54-58; 1977. (Pubitemid 8025869)
39. Thrower, J. S.; Hoffman, L.; Rechsteiner, M.; Pickart, C. M. Recognition of the polyubiquitin proteolytic signal. EMBO J. 19: 94-102; 2000. (Pubitemid 30009229)
40. Haas, A. L.; Warms, J. V.; Hershko, A.; Rose, I. A. Ubiquitin-activating enzyme: mechanism and role in protein-ubiquitin conjugation. J. Biol. Chem. 257: 2543-2548; 1982.
41. Kuhlbrodt, K.; Mouysset, J.; Hoppe, T. Orchestra for assembly and fate of polyubiquitin chains. Essays Biochem. 41: 1-14; 2005. (Pubitemid 41500967)
42. Ciechanover, A. The ubiquitin-proteasome proteolytic pathway. Cell 79: 13-21; 1994. (Pubitemid 24309509)
43. Smith, D. M.; Kafri, G.; Cheng, Y.; Ng, D.; Walz, T.; Goldberg, A. L. ATP binding to PAN or the 26S ATPases causes association with the 20S proteasome, gate opening, and translocation of unfolded proteins. Mol. Cell 20: 687-698; 2005. (Pubitemid 41740691)
44. Liu, C. W.; Li, X.; Thompson, D.; Wooding, K.; Chang, T. L.; Tang, Z.; Yu, H.; Thomas, P. J.; DeMartino, G. N. ATP binding and ATP hydrolysis play distinct roles in the function of 26S proteasome. Mol. Cell 24: 39-50; 2006. (Pubitemid 44466684)
45. Meller, R. The role of the ubiquitin proteasome system in ischemia and ischemic tolerance. Neuroscientist 15: 243-260; 2009.
46. Zungu, M.; Schisler, J. C.; Essop, M. F.; McCudden, C.; Patterson, C.; Willis, M. S. Regulation of AMPK by the ubiquitin proteasome system. Am. J. Pathol. 178: 4-11; 2011.
47. Hewitson, K. S.; McNeill, L. A.; Riordan, M. V.; Tian, Y. M.; Bullock, A. N.; Welford, R. W.; Elkins, J. M.; Oldham, N. J.; Bhattacharya, S.; Gleadle, J. M.; Ratcliffe, P. J.; Pugh, C. W.; Schofield, C. J. Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J. Biol. Chem. 277: 26351-26355; 2002. (Pubitemid 34967127)
48. Bhattacharya, S.; Michels, C. L.; Leung, M. K.; Arany, Z. P.; Kung, A. L.; Livingston, D. M. Functional role of p35srj, a novel p300/CBP binding protein, during transactivation by HIF-1. Genes Dev. 13: 64-75; 1999. (Pubitemid 29045116)
49. Kalousi, A.; Mylonis, I.; Politou, A. S.; Chachami, G.; Paraskeva, E.; Simos, G. Casein kinase 1 regulates human hypoxia-inducible factor HIF-1. J. Cell Sci. 123: 2976-2986; 2010.
50. Richard, D. E.; Berra, E.; Gothie, E.; Roux, D.; Pouyssegur, J. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J. Biol. Chem. 274: 32631-32637; 1999. (Pubitemid 129535289)
51. Mylonis, I.; Chachami, G.; Samiotaki, M.; Panayotou, G.; Paraskeva, E.; Kalousi, A.; Georgatsou, E.; Bonanou, S.; Simos, G. Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxia-inducible factor-1alpha. J. Biol. Chem. 281: 33095-33106; 2006. (Pubitemid 46043259)
52. Land, S. C.; Tee, A. R. Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J. Biol. Chem 282: 20534-20543; 2007. (Pubitemid 47100043)
53. Yasinska, I. M.; Sumbayev, V. V. S-nitrosation of Cys-800 of HIF-1alpha protein activates its interaction with p300 and stimulates its transcriptional activity. FEBS Lett 549: 105-109; 2003. (Pubitemid 36959853)
54. Carrero, P.; Okamoto, K.; Coumailleau, P.; O'Brien, S.; Tanaka, H.; Poellinger, L. Redox-regulated recruitment of the transcriptional coactivators CREB-binding protein and SRC-1 to hypoxia-inducible factor 1alpha. Mol. Cell. Biol. 20: 402-415; 2000. (Pubitemid 30002581)
55. Lando, D.; Pongratz, I.; Poellinger, L.; Whitelaw, M. L. A redox mechanism controls differential DNA binding activities of hypoxia-inducible factor (HIF) 1alpha and the HIF-like factor. J. Biol. Chem. 275: 4618-4627; 2000. (Pubitemid 30108846)
56. Liu, Y. V.; Baek, J. H.; Zhang, H.; Diez, R.; Cole, R. N.; Semenza, G. L. RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O2-independent and HSP90 inhibitor-induced degradation of HIF-1alpha. Mol. Cell 25: 207-217; 2007. (Pubitemid 46109612)
57. Liu, Y. V.; Hubbi, M. E.; Pan, F.; McDonald, K. R.; Mansharamani, M.; Cole, R. N.; Liu, J. O.; Semenza, G. L. Calcineurin promotes hypoxia-inducible factor 1alpha expression by dephosphorylating RACK1 and blocking RACK1 dimerization. J. Biol. Chem. 282: 37064-37073; 2007.
58. Flugel, D.; Gorlach, A.; Michiels, C.; Kietzmann, T. Glycogen synthase kinase 3 phosphorylates hypoxia-inducible factor 1alpha and mediates its desta-bilization in a VHL-independent manner. Mol. Cell. Biol 27: 3253-3265; 2007. (Pubitemid 46685205)
59. Flugel, D.; Gorlach, A.; Kietzmann, T. GSK-3beta regulates cell growth, migration, and angiogenesis via Fbw7 and USP28-dependent degradation of HIF-1alpha. Blood 119: 1292-1301; 2012.
60. Koh, M. Y.; Powis, G. Passing the baton: the HIF switch. Trends Biochem. Sci. 37: 364-372; 2012.
61. Bae, S. H.; Jeong, J. W.; Park, J. A.; Kim, S. H.; Bae, M. K.; Choi, S. J.; Kim, K. W. Sumoylation increases HIF-1a stability and its transcriptional activity. Biochem. Biophys. Res. Commun. 324: 394-400; 2004. (Pubitemid 39311508)
62. Belaiba, R. S.; Bonello, S.; Zahringer, C.; Schmidt, S.; Hess, J.; Kietzmann, T.; Gorlach, A. Hypoxia up-regulates hypoxia-inducible factor-1alpha transcription by involving phosphatidylinositol 3-kinase and nuclear factor kappaB in pulmonary artery smooth muscle cells. Mol. Biol. Cell. 18: 4691-4697; 2007. (Pubitemid 350246672)
63. Koong, A. C.; Chen, E. Y.; Giaccia, A. J. Hypoxia causes the activation of nuclear factor kappa B through the phosphorylation of I kappa B alpha on tyrosine residues. Cancer Res 54: 1425-1430; 1994. (Pubitemid 24106401)
64. Cummins, E. P.; Berra, E.; Comerford, K. M.; Ginouves, A.; Fitzgerald, K. T.; Seeballuck, F.; Godson, C.; Nielsen, J. E.; Moynagh, P.; Pouyssegur, J.; Taylor, C. T. Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. Proc. Natl. Acad. Sci. USA 103: 18154-18159; 2006. (Pubitemid 44871628)
65. Kasuno, K.; Takabuchi, S.; Fukuda, K.; Kizaka-Kondoh, S.; Yodoi, J.; Adachi, T.; Semenza, G. L.; Hirota, K. Nitric oxide induces hypoxia-inducible factor 1 activation that is dependent on MAPK and phosphatidylinositol 3-kinase signaling. J. Biol. Chem. 279: 2550-2558; 2004. (Pubitemid 38114240)
66. Ravi, R.; Mookerjee, B.; Bhujwalla, Z. M.; Sutter, C. H.; Artemov, D.; Zeng, Q.; Dillehay, L. E.; Madan, A.; Semenza, G. L.; Bedi, A. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 14: 34-44; 2000. (Pubitemid 30051577)
67. Bae, M. K.; Ahn, M. Y.; Jeong, J. W.; Bae, M. H.; Lee, Y. M.; Bae, S. K.; Park, J. W.; Kim, K. R.; Kim, K. W. Jab1 interacts directly with HIF-1alpha and regulates its stability. J. Biol. Chem. 277: 9-12; 2002. (Pubitemid 34952021)
68. Semenza, G. L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3: 721-732; 2003. (Pubitemid 37328811)
69. Nagel, S.; Papadakis, M.; Chen, R.; Hoyte, L. C.; Brooks, K. J.; Gallichan, D.; Sibson, N. R.; Pugh, C.; Buchan, A. M. Neuroprotection by dimethyloxalyl-glycine following permanent and transient focal cerebral ischemia in rats. J. Cereb. Blood Flow Metab. 31: 132-143; 2011.
70. Crapper McLachlan, D. R.; Dalton, A. J.; Kruck, T. P.; Bell, M. Y.; Smith, W. L.; Kalow, W.; Andrews, D. F. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 337: 1304-1308; 1991.
71. Ritchie, C. W.; Bush, A. I.; Mackinnon, A.; Macfarlane, S.; Mastwyk, M.; MacGregor, L.; Kiers, L.; Cherny, R.; Li, Q. X.; Tammer, A.; Carrington, D.; Mavros, C.; Volitakis, I.; Xilinas, M.; Ames, D.; Davis, S.; Beyreuther, K.; Tanzi, R. E.; Masters, C. L. Metal-protein attenuation with iodochlorhydrox- yquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch. Neurol. 60: 1685-1691; 2003. (Pubitemid 37521621)
72. Bowern, N.; Ramshaw, I. A.; Clark, I. A.; Doherty, P. C. Inhibition of autoimmune neuropathological process by treatment with an iron-chelating agent. J. Exp. Med. 160: 1532-1543; 1984. (Pubitemid 15220781)
73. Kaur, D.; Andersen, J. Does cellular iron dysregulation play a causative role in Parkinson's disease? Ageing Res. Rev 3: 327-343; 2004. (Pubitemid 38844698)
74. Zaman, K.; Ryu, H.; Hall, D.; O'Donovan, K.; Lin, K. I.; Miller, M. P.; Marquis, J. C.; Baraban, J. M.; Semenza, G. L.; Ratan, R. R. Protection from oxidative stress-induced apoptosis in cortical neuronal cultures by iron chelators is associated with enhanced DNA binding of hypoxia-inducible factor-1 and ATF-1/CREB and increased expression of glycolytic enzymes, p21(waf1/cip1), and erythropoietin. J. Neurosci. 19: 9821-9830; 1999. (Pubitemid 30226655)
75. Li, D.; Bai, T.; Brorson, J. R. Adaptation to moderate hypoxia protects cortical neurons against ischemia-reperfusion injury and excitotoxicity independently of HIF-1a. Exp. Neurol 230: 302-310; 2011.
76. Lomb, D. J.; Straub, J. A.; Freeman, R. S. Prolyl hydroxylase inhibitors delay neuronal cell death caused by trophic factor deprivation. J. Neurochem. 103: 1897-1906; 2007. (Pubitemid 350130097)
77. Niatsetskaya, Z.; Basso, M.; Speer, R. E.; McConoughey, S. J.; Coppola, G.; Ma, T. C.; Ratan, R. R. HIF prolyl hydroxylase inhibitors prevent neuronal death induced by mitochondrial toxins: therapeutic implications for Huntington's disease and Alzheimer's disease. Antioxid. Redox Signaling 12: 435-443; 2010.
78. Smirnova, N. A.; Rakhman, I.; Moroz, N.; Basso, M.; Payappilly, J.; Kazakov, S.; Hernandez-Guzman, F.; Gaisina, I. N.; Kozikowski, A. P.; Ratan, R. R.; Gazaryan, I. G. Utilization of an in vivo reporter for high throughput identification of branched small molecule regulators of hypoxic adaptation. Chem. Biol. 17: 380-391; 2010.
79. Lee, D. W.; Rajagopalan, S.; Siddiq, A.; Gwiazda, R.; Yang, L.; Beal, M. F.; Ratan, R. R.; Andersen, J. K. Inhibition of prolyl hydroxylase protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity: model for the potential involvement of the hypoxia-inducible factor pathway in Parkinson disease. J. Biol. Chem. 284: 29065-29076; 2009.
80. Tian, Y. M.; Yeoh, K. K.; Lee, M. K.; Eriksson, T.; Kessler, B. M.; Kramer, H. B.; Edelmann, M. J.; Willam, C.; Pugh, C. W.; Schofield, C. J.; Ratcliffe, P. J. Differential sensitivity of hypoxia inducible factor hydroxylation sites to hypoxia and hydroxylase inhibitors. J. Biol. Chem. 286: 13041-13051; 2011.
81. Stanciu, M.; Wang, Y.; Kentor, R.; Burke, N.; Watkins, S.; Kress, G.; Reynolds, I.; Klann, E.; Angiolieri, M. R.; Johnson, J. W.; DeFranco, D. B. Persistent activation of ERK contributes to glutamate-induced oxidative toxicity in a neuronal cell line and primary cortical neuron cultures. J. Biol. Chem. 275: 12200-12206; 2000. (Pubitemid 30237798)
82. Basso, M.; Berlin, J.; Xia, L.; Sleiman, S. F.; Ko, B.; Haskew-Layton, R.; Kim, E.; Antonyak, M. A.; Cerione, R. A.; Iismaa, S. E.; Willis, D.; Cho, S.; Ratan, R. R. Transglutaminase inhibition protects against oxidative stress-induced neu-ronal death downstream of pathological ERK activation. J. Neurosci. 32: 6561-6569; 2012.
83. Ratan, R. R.; Murphy, T. H.; Baraban, J. M. Macromolecular synthesis inhibitors prevent oxidative stress-induced apoptosis in embryonic cortical neurons by shunting cysteine from protein synthesis to glutathione. J. Neurosci 14: 4385-4392; 1994. (Pubitemid 24200560)
84. Siddiq, A.; Aminova, L. R.; Troy, C. M.; Suh, K.; Messer, Z.; Semenza, G. L.; Ratan, R. R. Selective inhibition of hypoxia-inducible factor (HIF) prolyl-hydroxylase 1 mediates neuroprotection against normoxic oxidative death via HIF- and CREB-independent pathways. J. Neurosci. 29: 8828-8838; 2009.
85. Roger, V. L.; Go, A. S.; Lloyd-Jones, D. M.; Adams, R. J.; Berry, J. D.; Brown, T. M.; Carnethon, M. R.; Dai, S.; de Simone, G.; Ford, E. S.; Fox, C. S.; Fullerton, H. J.; Gillespie, C.; Greenlund, K. J.; Hailpern, S. M.; Heit, J. A.; Ho, P. M.; Howard, V. J.; Kissela, B. M.; Kittner, S. J.; Lackland, D. T.; Lichtman, J. H.; Lisabeth, L. D.; Makuc, D. M.; Marcus, G. M.; Marelli, A.; Matchar, D. B.; McDermott, M. M.; Meigs, J. B.; Moy, C. S.; Mozaffarian, D.; Mussolino, M. E.; Nichol, G.; Paynter, N. P.; Rosamond, W. D.; Sorlie, P. D.; Stafford, R. S.; Turan, T. N.; Turner, M. B.; Wong, N. D.; Wylie-Rosett, J. Heart disease and stroke statistics - 2011 update: a report from the American Heart Association. Circulation 123:e18-e209; 2011.
86. Magistretti, P. J.; Pellerin, L.; Rothman, D. L.; Shulman, R. G. Energy on demand. Science 283: 496-497; 1999.
87. Prins, M. L. Cerebral metabolic adaptation and ketone metabolism after brain injury. J. Cereb. Blood Flow Metab. 28: 1-16; 2008.
88. Faria, M. H.; Muniz, L. R.; Vasconcelos, P. R. Ketone bodies metabolism during ischemic and reperfusion brain injuries following bilateral occlusion of common carotid arteries in rats. Acta Cir. Bras 22: 125-129; 2007. (Pubitemid 46597122)
89. Hofer, R. E.; Wagner, S. R. t.; Pasternak, J. J.; Albrecht 2nd R. F.; Gallagher, W. J.; Lanier, W. L. Fructose-1,6-bisphosphate and fructose-2,6-bisphosphate do not influence brain carbohydrate or high-energy phosphate metabolism in a rat model of forebrain ischemia. J. Neurosurg. Anesthesiol. 21: 31-39; 2009.
90. Tymianski, M. Emerging mechanisms of disrupted cellular signaling in brain ischemia. Nat. Neurosci. 14: 1369-1373; 2011.
91. Besancon, E.; Guo, S.; Lok, J.; Tymianski, M.; Lo, E. H. Beyond NMDA and AMPA glutamate receptors: emerging mechanisms for ionic imbalance and cell death in stroke. Trends Pharmacol. Sci. 29: 268-275; 2008.
92. Iadecola, C.; Anrather, J. The immunology of stroke: from mechanisms to translation. Nat. Med 17: 796-808; 2011.
93. Bruer, U.; Weih, M. K.; Isaev, N. K.; Meisel, A.; Ruscher, K.; Bergk, A.; Trendelenburg, G.; Wiegand, F.; Victorov, I. V.; Dirnagl, U. Induction of tolerance in rat cortical neurons: hypoxic preconditioning. FEBS Lett. 414: 117-121; 1997. (Pubitemid 27380366)
94. Sharp, F. R.; Ran, R.; Lu, A.; Tang, Y.; Strauss, K. I.; Glass, T.; Ardizzone, T.; Bernaudin, M. Hypoxic preconditioning protects against ischemic brain injury. NeuroRx 1: 26-35; 2004. (Pubitemid 46613775)
95. Ratan, R. R.; Siddiq, A.; Aminova, L.; Lange, P. S.; Langley, B.; Ayoub, I.; Gensert, J.; Chavez, J. Translation of ischemic preconditioning to the patient: prolyl hydroxylase inhibition and hypoxia inducible factor-1 as novel targets for stroke therapy. Stroke 35: 2687-2689; 2004. (Pubitemid 39458369)
96. Stowe, A. M.; Plautz, E. J.; Nguyen, P.; Frost, S. B.; Eisner-Janowicz, I.; Barbay, S.; Dancause, N.; Sensarma, A.; Taylor, M. D.; Zoubina, E. V.; Nudo, R. J. Neuronal HIF-1 alpha protein and VEGFR-2 immunoreactivity in functionally related motor areas following a focal M1 infarct. J. Cereb. Blood Flow Metab. 28: 612-620; 2008. (Pubitemid 351304272)
97. Chavez, J. C.; LaManna, J. C. Activation of hypoxia-inducible factor-1 in the rat cerebral cortex after transient global ischemia: potential role of insulinlike growth factor-1. J. Neurosci 22: 8922-8931; 2002. (Pubitemid 35379062)
98. Baranova, O.; Miranda, L. F.; Pichiule, P.; Dragatsis, I.; Johnson, R. S.; Chavez, J. C. Neuron-specific inactivation of the hypoxia inducible factor 1 alpha increases brain injury in a mouse model of transient focal cerebral ischemia. J. Neurosci. 27: 6320-6332; 2007. (Pubitemid 46890035)
99. Wu, Y.; Li, X.; Xie, W.; Jankovic, J.; Le, W.; Pan, T. Neuroprotection of deferoxamine on rotenone-induced injury via accumulation of HIF-1 alpha and induction of autophagy in SH-SY5Y cells. Neurochem. Int. 57: 198-205; 2010.
100. Chen, W.; Jadhav, V.; Tang, J.; Zhang, J. H. HIF-1alpha inhibition ameliorates neonatal brain injury in a rat pup hypoxic-ischemic model. Neurobiol. Dis. 31: 433-441; 2008.
101. Higashida, T.; Peng, C.; Li, J.; Dornbos 3rd D.; Teng, K.; Li, X.; Kinni, H.; Guthikonda, M.; Ding, Y. Hypoxia-inducible factor-1alpha contributes to brain edema after stroke by regulating aquaporins and glycerol distribution in brain. Curr. Neurovasc. Res. 8: 44-51; 2011.
102. Yeh, S. H.; Ou, L. C.; Gean, P. W.; Hung, J. J.; Chang, W. C. Selective inhibition of early - but not late - expressed HIF-1alpha is neuroprotective in rats after focal ischemic brain damage. Brain Pathol. 21: 249-262; 2011.
103. Aminova, L. R.; Chavez, J. C.; Lee, J.; Ryu, H.; Kung, A.; Lamanna, J. C.; Ratan, R. R. Prosurvival and prodeath effects of hypoxia-inducible factor-1alpha stabilization in a murine hippocampal cell line. J. Biol. Chem. 280: 3996-4003; 2005. (Pubitemid 40223869)
104. Guo, S.; Miyake, M.; Liu, K. J.; Shi, H. Specific inhibition of hypoxia inducible factor 1 exaggerates cell injury induced by in vitro ischemia through deteriorating cellular redox environment. J. Neurochem 108: 1309-1321; 2009.
105. Vangeison, G.; Carr, D.; Federoff, H. J.; Rempe, D. A. The good, the bad, and the cell type-specific roles of hypoxia inducible factor-1 alpha in neurons and astrocytes. J. Neurosci. 28: 1988-1993; 2008. (Pubitemid 351302661)
106. Wouters, B. G.; Koritzinsky, M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat. Rev. Cancer 8: 851-864; 2008.
107. Osada-Oka, M.; Hashiba, Y.; Akiba, S.; Imaoka, S.; Sato, T. Glucose is necessary for stabilization of hypoxia-inducible factor-1alpha under hypoxia: contribution of the pentose phosphate pathway to this stabilization. FEBS Lett 584: 3073-3079; 2010.
108. Sudarshan, S.; Sourbier, C.; Kong, H. S.; Block, K.; Valera Romero, V. A.; Yang, Y.; Galindo, C.; Mollapour, M.; Scroggins, B.; Goode, N.; Lee, M. J.; Gourlay, C. W.; Trepel, J.; Linehan, W. M.; Neckers, L. Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species. Mol. Cell. Biol. 29: 4080-4090; 2009.
109. Ryu, J. H.; Li, S. H.; Park, H. S.; Park, J. W.; Lee, B.; Chun, Y. S. Hypoxia-inducible factor alpha subunit stabilization by NEDD8 conjugation is reactive oxygen species-dependent. J. Biol. Chem. 286: 6963-6970; 2011.
110. Karuppagounder, S.S.; Basso, M.; Sleiman, S.F.; Ma, T.C.; Speer, R.E.; Smirnova, N.A.; Gazaryan, I.G.; Ratan, R.R. In vitro ischemia suppresses hypoxic induction of hypoxia inducible factor-1a by inhibitionofsynthesis and not enhanced degradation. J. Neurosci. Res., http://dx.doi.org/10.1002/jnr.23204, in press.
111. Ratan, R. R.; Siddiq, A.; Aminova, L.; Langley, B.; McConoughey, S.; Karpisheva, K.; Lee, H. H.; Carmichael, T.; Kornblum, H.; Coppola, G.; Geschwind, D. H.; Hoke, A.; Smirnova, N.; Rink, C.; Roy, S.; Sen, C.; Beattie, M. S.; Hart, R. P.; Grumet, M.; Sun, D.; Freeman, R. S.; Semenza, G. L.; Gazaryan, I. Small molecule activation of adaptive gene expression: tilorone or its analogs are novel potent activators of hypoxia inducible factor-1 that provide prophylaxis against stroke and spinal cord injury. Ann. N. Y. Acad. Sci. 1147: 383-394; 2008.
112. Safran, M.; Kim, W. Y.; O'Connell, F.; Flippin, L.; Gunzler, V.; Horner, J. W.; Depinho, R. A.; Kaelin Jr. W. G. Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production. Proc. Natl. Acad. Sci. USA 103: 105-110; 2006. (Pubitemid 43076112)
113. Moroz, E.; Carlin, S.; Dyomina, K.; Burke, S.; Thaler, H. T.; Blasberg, R.; Serganova, I. Real-time imaging of HIF-1alpha stabilization and degradation. PLoS One 4:e5077; 2009.
114. Arquier, N.; Vigne, P.; Duplan, E.; Hsu, T.; Therond, P. P.; Frelin, C.; D'Angelo, G. Analysis of the hypoxia-sensing pathway in Drosophila melanogaster. Biochem. J. 393: 471-480; 2006. (Pubitemid 43099086)
115. Chua, Y. L.; Dufour, E.; Dassa, E. P.; Rustin, P.; Jacobs, H. T.; Taylor, C. T.; Hagen, T. Stabilization of hypoxia-inducible factor-1alpha protein in hypoxia occurs independently of mitochondrial reactive oxygen species production. J. Biol. Chem. 285: 31277-31284; 2010.
116. Smirnova, N. A.; Hushpulian, D. M.; Speer, R. E.; Gaisina, I. N.; Ratan, R. R.; Gazaryan, I. G. Catalytic mechanism and substrate specificity of HIF prolyl hydroxylases. Biochemistry (Moscow) 77: 1108-1119; 2012.
117. Goldman, S. J.; Chen, E.; Taylor, R.; Zhang, S.; Petrosky, W.; Reiss, M.; Jin, S. Use of the ODD-luciferase transgene for the non-invasive imaging of spontaneous tumors in mice. PLoS One 6:e18269; 2011.
118. Karuppagounder, S. S.; Ratan, R. R. Hypoxia-inducible factor prolyl hydro-xylase inhibition: robust new target or another big bust for stroke therapeutics? J. Cereb. Blood Flow Metab 32: 1347-1361; 2012.
119. Prass, K.; Ruscher, K.; Karsch, M.; Isaev, N.; Megow, D.; Priller, J.; Scharff, A.; Dirnagl, U.; Meisel, A. Desferrioxamine induces delayed tolerance against ogy and Medicine 62 (2013) 26-36 cerebral ischemia in vivo and in vitro. J. Cereb. Blood Flow Metab. 22: 520-525; 2002. (Pubitemid 34477773)
120. Hamrick, S. E.; McQuillen, P. S.; Jiang, X.; Mu, D.; Madan, A.; Ferriero, D. M. A role for hypoxia-inducible factor-1alpha in desferoxamine neuroprotection. Neurosci. Lett. 379: 96-100; 2005.
121. Li, Y. X.; Ding, S. J.; Xiao, L.; Guo, W.; Zhan, Q. Desferoxamine preconditioning protects against cerebral ischemia in rats by inducing expressions of hypoxia inducible factor 1 alpha and erythropoietin. Neurosci. Bull 24: 89-95; 2008. (Pubitemid 351738284)
122. Ma, T. C.; Langley, B.; Ko, B.; Wei, N.; Gazaryan, I. G.; Zareen, N.; Yamashiro, D. J.; Willis, D. E.; Ratan, R. R. A screen for inducers of p21(waf1/cip1) identifies HIF prolyl hydroxylase inhibitors as neuroprotective agents with antitumor properties. Neurobiol. Dis. 49C: 13-21; 2012.
123. Regan, R. F.; Panter, S. S. Hemoglobin potentiates excitotoxic injury in cortical cell culture. J. Neurotrauma 13: 223-231; 1996. (Pubitemid 26142615)
124. Almli, L. M.; Hamrick, S. E.; Koshy, A. A.; Tauber, M. G.; Ferriero, D. M. Multiple pathways of neuroprotection against oxidative stress and excito-toxic injury in immature primary hippocampal neurons. Brain Res. Dev. Brain Res. 132: 121-129; 2001. (Pubitemid 34024954)
125. Farinelli, S. E.; Greene, L. A. Cell cycle blockers mimosine, ciclopirox, and deferoxamine prevent the death of PC12 cells and postmitotic sympathetic neurons after removal of trophic support. J. Neurosci 16: 1150-1162; 1996. (Pubitemid 26140872)
126. Bergeron, M.; Gidday, J. M.; Yu, A. Y.; Semenza, G. L.; Ferriero, D. M.; Sharp, F. R. Role of hypoxia-inducible factor-1 in hypoxia-induced ischemic tolerance in neonatal rat brain. Ann. Neurol. 48: 285-296; 2000.
127. Mu, D.; Chang, Y. S.; Vexler, Z. S.; Ferriero, D. M. Hypoxia-inducible factor 1a and erythropoietin upregulation with deferoxamine salvage after neonatal stroke. Exp. Neurol. 195: 407-415; 2005. (Pubitemid 41297792)
128. Freret, T.; Valable, S.; Chazalviel, L.; Saulnier, R.; Mackenzie, E. T.; Petit, E.; Bernaudin, M.; Boulouard, M.; Schumann-Bard, P. Delayed administration of deferoxamine reduces brain damage and promotes functional recovery after transient focal cerebral ischemia in the rat. Eur. J. Neurosci. 23: 1757-1765; 2006.
129. Hanson, L. R.; Roeytenberg, A.; Martinez, P. M.; Coppes, V. G.; Sweet, D. C.; Rao, R. J.; Marti, D. L.; Hoekman, J. D.; Matthews, R. B.; Frey 2nd W. H.; Panter, S. S. Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke. J. Pharmacol. Exp. Ther. 330: 679-686; 2009.
130. Zhao, Y.; Rempe, D. A. Prophylactic neuroprotection against stroke: low-dose, prolonged treatment with deferoxamine or deferasirox establishes prolonged neuroprotection independent of HIF-1 function. J. Cereb. Blood Flow Metab 31: 1412-1423; 2010.
131. Chu, P. W.; Beart, P. M.; Jones, N. M. Preconditioning protects against oxidative injury involving hypoxia-inducible factor-1 and vascular endothe-lial growth factor in cultured astrocytes. Eur. J. Pharmacol. 633: 24-32; 2010.
132. Ogle, M. E.; Gu, X.; Espinera, A. R.; Wei, L. Inhibition of prolyl hydroxylases by dimethyloxaloylglycine after stroke reduces ischemic brain injury and requires hypoxia inducible factor-1a. Neurobiol. Dis. 45: 733-742; 2012.
133. Zheng, H.; Blat, D.; Fridkin, M. Novel neuroprotective neurotrophic NAP analogs targeting metal toxicity and oxidative stress: potential candidates for the control of neurodegenerative diseases. J. Neural Transm. Suppl. 71: 163-172; 2006. (Pubitemid 351412118)
134. Youdim, M. B.; Stephenson, G.; Ben Shachar, D. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chela-tors: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann. N. Y. Acad. Sci 1012: 306-325; 2004. (Pubitemid 38453534)
135. Chinta, S. J.; Rajagopalan, S.; Ganesan, A.; Andersen, J. K. A possible novel anti-inflammatory mechanism for the pharmacological prolyl hydroxylase inhibitor 3,4-dihydroxybenzoate: implications for use as a therapeutic for Parkinson's disease. Parkinsons Dis 2012: 364684; 2012.
136. Guo, C.; Wang, T.; Zheng, W.; Shan, Z. Y.; Teng, W. P.; Wang, Z. Y. Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloi-dogenic APP processing in a transgenic mouse model of Alzheimer's disease. Neurobiol. Aging 34: 562-575; 2013.
137. Fine, J. M.; Baillargeon, A. M.; Renner, D. B.; Hoerster, N. S.; Tokarev, J.; Colton, S.; Pelleg, A.; Andrews, A.; Sparley, K. A.; Krogh, K. M.; Frey, W. H.; Hanson, L. R. Intranasal deferoxamine improves performance in radial arm water maze, stabilizes HIF-1alpha, and phosphorylates GSK3beta in P301L tau transgenic mice. Exp. Brain Res. 219: 381-390; 2012.
138. Yang, Y. T.; Ju, T. C.; Yang, D. I. Induction of hypoxia inducible factor-1 attenuates metabolic insults induced by 3-nitropropionic acid in rat C6 glioma cells. J. Neurochem 93: 513-525; 2005.
139. Wong, A.; Yang, J.; Cavadini, P.; Gellera, C.; Lonnerdal, B.; Taroni, F.; Cortopassi, G. The Friedreich's ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis. Hum. Mol. Genet 8: 425-430; 1999. (Pubitemid 29097330)
140. Li, K.; Besse, E. K.; Ha, D.; Kovtunovych, G.; Rouault, T. A. Iron-dependent regulation of frataxin expression: implications for treatment of Friedreich ataxia. Hum. Mol. Genet 17: 2265-2273; 2008.)